Erythropoietin Drugs Market - Historic Data (2019-2024), Global Trends 2025, Growth Forecasts 2037
Erythropoietin Drugs Market in 2025 is assessed at USD 11.37 billion. The global market size was worth around USD 10.95 billion in 2024 and is set to register a CAGR of more than 4.8%, exceeding USD 20.14 billion revenue by 2037. North America is expected to total USD 5.36 billion by 2037, due to the high prevalence rates of chronic CKD and cancer, which often result in anemia.
The primary growth driver of the erythropoietin drugs market is the increasing prevalence of chronic diseases that lead to anemia, such as chronic kidney disease (CKD) and cancer. These conditions often reduce the body’s ability to produce red blood cells, making EPO drugs essential for managing anemia. A hospital-based study on the prevalence of anemia published by the National Library of Medicine (NLM) in 2023, reported that anemia in CKD is prevalent at 14% in the United States, 39.36% in India, 51.5% in China, 43.18% in South Africa, and 79% in Cameroon. Furthermore, the prevalence rises with CKD stage, with overall rates of 22.4%, 41.3%, and 53.9% in stages 3, 4, and 5, respectively.
Moreover, the rising incidence of CKD and cancer is a significant driver for the erythropoietin drugs market. Both conditions are closely associated with anemia, as CKD can impair kidney function, and cancer treatments, such as chemotherapy, can damage bone marrow and decrease red blood cell production. Anemia is prevalent among cancer patients, accounting for more than 40% of cases. This creates a demand for EPO drugs, which help stimulate red blood cell production and manage anemia symptoms, improving the quality of life for patients.
